Global Information
회사소개 | 문의 | 비교리스트

세계의 비알콜성 지방간염(NASH) 치료제 및 진단 시장 : 파이프라인 치료제, 진단 기술, 치료법, 지역별 - 성장, 동향, 예측(2018-2023년)

Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2019년 05월 상품 코드 649745
페이지 정보 영문
US $ 4,250 ₩ 5,129,000 PDF (Single User License)
US $ 4,750 ₩ 5,733,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,242,000 PDF (Site License)
US $ 7,500 ₩ 9,052,000 PDF (Corporate License)

세계의 비알콜성 지방간염(NASH) 치료제 및 진단 시장 : 파이프라인 치료제, 진단 기술, 치료법, 지역별 - 성장, 동향, 예측(2018-2023년) Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)
발행일 : 2019년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 비알콜성 지방간염(NASH) 치료제 및 진단 시장은 2018-2023년간 25.0%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 당뇨병 및 비만 유병률 상승, 연구개발 투자 증가 등에 의해 시장 성장이 촉진되고 있습니다. 지역별로는 새로운 의료 기술 도입률이 높고, 의료 인프라가 정비되어 연구개발이 활성화된 북미 지역이 최대 시장으로 부상하고 있습니다.

세계의 비알콜성 지방간염(NASH: Nonalcoholic Steatohepatitis) 시장을 조사했으며, 시장 개요, 기술·용도·지역별 시장 동향, 시장 규모 추이와 예측, 성장 촉진요인 및 저해요인, 시장 기회와 과제, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.


제1장 서론

  • 시장 정의

제2장 조사 방법

제3장 주요 요약

제4장 주요 영향요인

제5장 시장 개요

  • 현재의 시장 시나리오
  • Five Forces 분석
    • 구매자의 협상력
    • 공급 기업의 협상력
    • 신규 진출기업의 위협
    • 대체품의 위협
    • 경쟁 기업간 경쟁 관계

제6장 시장 역학

  • 성장 촉진요인
    • NASH 치료제의 유망한 파이프라인
    • 세계적인 당뇨병 및 비만 이환율 상승
    • 새로운 바이오마커 기술의 등장과 간 생검 기술의 향상
  • 성장 저해요인
    • 비알코올성 지방성간질환(NAFLD)에 대한 효과적인 진단법 부재
    • 치료 분야에서의 기술 진보 정체
  • 시장 기회
  • 주요 과제

제7장 비알콜성 지방간염(NASH) 시장 : 부문별

  • 파이프라인 치료제별
    • III상 시험
      • Obeticholic Acid (OCA)
      • Aramchol (arachidyl amido cholanoic acid)
      • Saroglitazar
      • Elafibranor
      • 기타
  • 진단 기술별
    • 영상
    • 간 생검
    • 바이오마커 진단
    • 기타
  • 치료법별
    • 약물요법
    • 인슐린 저항성 개선 치료
    • 항사이토카인 요법
    • 외과 수술
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제8장 경쟁 구도

  • 인수합병 분석
  • 합의·제휴·협력
  • 신제품 출시

제9장 주요 기업

  • AstraZeneca PLC
  • Conatus Pharmaceuticals, Inc.
  • Enzo Biochem, Inc.
  • Galmed Pharmaceuticals Ltd
  • Genfit Corp.
  • Gilead
  • Horizon Pharma PLC
  • Immuron
  • Intercept Pharmaceuticals, Inc.
  • Novo Nordisk A/S

제10장 시장 전망

제11장 면책사항

LSH 18.06.18

Market Overview

The non-alcoholic steatohepatitis therapeutics and diagnostics market was valued at USD 7932.91 million in 2018 and is expected to reach USD 26776.58 million by 2024, with an anticipated CAGR of 25.89%, during the forecast period (2019-2024). The major factors driving the growth of the market studied are the increase in nash-affected population, the rising global prevalence of diabetic and obese populations, and increasing awareness about NAFLD/NASH. Currently, there are no FDA-approved therapies for NASH. Hence, there is a huge need to find appropriate therapeutic targets for the treatment of NASH. However, the understanding of the pathogenesis and progression of NASH has evolved and several promising novel therapies associated with the same are being evaluated. However, there is no specialized diagnostic test available in the market for NAFLD, and thus, the lack of effective diagnostic tests for non-alcoholic fatty liver disease, the slow advancements in the therapeutics field has been limiting the growth of the market.

Scope of the Report

Non-alcoholic steatohepatitis (NASH) is a type of NAFLD. NASH is the liver inflammation and damage caused by the buildup of fat in the liver. It is part of a group of conditions called non-alcoholic fatty liver disease (NAFLD). The products used in the diagnosis and treatment are covered under this report.

Key Market Trends

Selonsertib is Expected to Experience a Lucrative Growth During the Forecast Period

Selonsertib is an orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic, and anti-fibrotic activities. The major factors driving the growth of the market are the rising prevalence of NASH across the world. The drug targets and binds to the catalytic kinase domain of ASK1 in an ATP-competitive manner, thereby preventing its phosphorylation and activation. It plays a vital role in the development of certain cardiovascular and neurodegenerative diseases, diabetes, and certain types of cancer. In February 2019, one of the market players, Gilead Sciences, announced that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, in patients with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH), did not achieve its primary endpoint. Thus, in April 2019, it failed the Phase 3 trial, again. However, the drug was generally well tolerated, and safety results were consistent with previous studies. The company is making considerable investments in the development of drugs for NASH. Recently, in April 2019, Gilead Sciences used the AI-based platform of insitro to discover and develop treatments for NASH. Therefore, such type of activities is expected to increase the process of drug development, leading to rapid approval of the drug over the forecast period.

North America Dominates the NASH Therapeutics and Diagnostics Market

The North America market is expected to witness a CAGR of 26.12% during the forecast period. The prevalence of the nonalcoholic fatty liver disease is due to the rising trend of obesity in the region. Nonalcoholic fatty liver disease (steatohepatitis) is considered as the most common form of chronic liver disease. According to a study conducted by the Intermountain Healthcare researchers, on the economic impact of the disease, the nonalcoholic fatty liver disease affects approximately 100 million Americans every year, and the cost of the disease impacting the US healthcare system is nearly USD 32 billion, annually. Another driving factor is the rising number of obese patients in the country. For instance, as per the OECD data, 47% of the adult population in the United States may suffer from obesity by 2030, as compared to 37.7% in 2014. This represents an estimated 25% increase in obesity, by 2030. Therefore, with an increasing number of patients, the diagnostics and therapeutics are also expected to rise in the future in North America.

Competitive Landscape

Several major players, such as Galmed, Intercept, Genfit, Conatus, MediciNova, and Shire, among others, have their NASH drugs in the last stage of clinical trials. The ongoing scientific developments in the pathogenesis of NASH and the identification of novel agents targeting the disease activities are necessary for the further expansion of capacities to treat NASH and to reduce long-term clinical outcomes, such as cirrhosis, liver failure, and cancer. Investors and analysts are still somewhat skeptical about the approval chances of many of the most advanced NASH candidates. Apart from demonstrating the safety and efficacy of NASH treatments, the companies are also dealing with pricing decisions. The NASH pipeline is, therefore, worth keeping an eye on, owing to the rising prevalence of the disease, lack of available proper treatments, and the developing treatment landscape.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in NASH-affected Population
    • 4.2.2 Rising Global Prevalence of Diabetic and Obese Populations
    • 4.2.3 Increasing Awareness about NAFLD/NASH
  • 4.3 Market Restraints
    • 4.3.1 Lack of Effective Diagnostics for Non-alcoholic Fatty Liver Disease (NAFLD)
    • 4.3.2 Slow Advancements in the Therapeutic Field
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Product
    • 5.1.1 Therapeutics
      • Elafibranor
      • Ocaliva
      • Selonsertib
      • Cenicriviroc
      • Emricasan
      • Other Therapeutics
    • 5.1.2 Diagnostics
      • Imaging Techniques
      • Diagnostic Tests
      • Biopsy
  • 5.2 Geography
    • 5.2.1 North America
      • US
      • Canada
      • Mexico
    • 5.2.2 Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.2.3 Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • 5.2.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Allergan PLC
    • 6.1.2 Novartis AG
    • 6.1.3 Madrigal Pharmaceuticals
    • 6.1.4 Galmed Pharmaceuticals
    • 6.1.5 Intercept Pharmaceuticals Inc.
    • 6.1.6 Gilead Sciences Inc.
    • 6.1.7 Genfit SA
    • 6.1.8 Novo Nordisk A/S
    • 6.1.9 Zydus Cadila
    • 6.1.10 Merck & Co.
    • 6.1.11 Viking Therapeutics


Back to Top
전화 문의